PCSK9 Inhibition to Lower LDL-Cholesterol and Reduce Cardiovascular Risk: Great Expectations.

New clinical trials with the proprotein convertase subtilisin- kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab show that these drugs not only lower lowdensity lipoprotein cholesterol (LDL-C) profoundly, but also seem to reduce cardiovascular events, although the number of events and duration of follow-up are limited. Larger trials are underway to confirm these findings and to document safety